Contact: Dennis J. Curtin, Senior Vice President - Chief Financial Officer
Telephone: 1-800-544-4624, ext. 320
Email: dcurtin@ezem.com

E-Z-EM, Inc. Announces Results for the First Quarter 2003

Westbury, New York; October 15, 2002 E-Z-EM, Inc., (Amex: EZM.A and EZM.B) announced today 
results for the first fiscal quarter ended August 31, 2002. The Company reported net sales 
of $30,280,000, as compared to net sales of $27,641,000 for the first fiscal quarter of 2002. 
The Company’s sales rose on strong performance by AngioDynamics and continued strength in 
CT imaging products. 

The Company reported a net loss for the quarter of $741,000, or ($.07) per basic and diluted 
share. In the first quarter of fiscal 2002, the Company reported a net loss of $112,000 or 
($.01) per basic and diluted share. Results for the quarter were adversely affected by a 
decrease in procedure volumes in core radiographic and fluoroscopic procedures, and by 
increased operating expenses of $2,670,000. Included in these expenses was $582,000 related 
to the previously announced plan to merge the Company's two currently outstanding classes of 
common stock into a single class of common stock. Operating expenses were also affected by 
the Company’s continued investments in several growth areas, namely the interventional 
radiology, CT injector, and virtual colonoscopy product lines.

Commenting on the quarterly results, Anthony A. Lombardo, E-Z-EM President and CEO stated, "We 
continue to implement our strategic plan by investing in growing market segments, and our 
first quarter results reflect ongoing investments in several core areas. Our focus on the 
growing CT marketplace, including contrast products, CT injectors and the development of 
virtual colonoscopy products, and on the sales, marketing and manufacturing infrastructure to 
support these programs, we believe will have a positive impact on sales in succeeding quarters. 
Higher operating expenses related to these investments, coupled with continued declines in 
X-ray fluoroscopy procedures, negatively impacted the quarter.

"We are pleased with the continued strong performance of our AngioDynamics subsidiary, which 
had record sales for the quarter and operating profit of $560,000 that more than doubled from 
last year’s quarter. Revenues from U.S. sales increased 24% from the comparable quarter of 
last year. Sales growth was led by increased sales of products such as the MoreFlowTM dialysis 
catheter, Workhorse(TM) PTA balloon catheters, and Accu-VuTM sizing catheters - all products 
introduced within the last two years."

Mr. Lombardo further commented, "We have embarked on a strategy to position the Company in 
new growth areas. As part of this strategy, we believe the action taken by our Board of 
Directors to recommend the merger of the Company's two currently outstanding classes of 
common sock into a single class of common stock will assist the Company in providing the 
capital structure for greater market visibility, and will support the investments being made 
in new product areas to grow the Company and provide for long-term shareholder value." 

The Company’s cash and short-term marketable securities at August 31, 2002 were $19.7 million, 
down $4.4 million from the year ended June 1, 2002. Net book value was $8.16 per basic share 
at August 31, 2002. The Company’s balance sheet and financial position remain strong.

About E-Z-EM, Inc.

E-Z-EM is the world’s largest manufacturer of contrast agents for gastrointestinal radiology. 
The Company has developed the only CT injector on the market that can help detect contrast 
extravasation, the EmpowerCTTM with patented EDA(TM) technology; it also offers a complete 
tool kit for the virtual colonoscopy practitioner. This product line consists of virtual 
colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and 
a carbon dioxide colon insufflation system. E-Z-EM’s wholly-owned subsidiary, AngioDynamics, 
manufactures a wide range of products, including angiographic, vascular access, thrombolytic, 
angioplasty, stents, as well as abdominal infection drainage products. AngioDynamics’ focus 
is on diagnostic and therapeutic products for interventional radiology and other areas of 
minimally invasive surgery. Enteric Products, Inc., another subsidiary, develops, manufactures 
and markets tests for detection of the ulcer- and cancer-causing bacterium Helicobacter 
pylori. For additional information, please contact Tom Johnson at 1-800-544-4624, ext. 317, 
(E-mail: tjohnson@ezem.com) or visit our corporate web site at www.ezem.com.

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", 
"believes", "seeks", "estimates," or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the 
risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not 
limited to its Form 10-Q for the quarter ended September 1, 2001,as well as its Annual Report 
on Form 10-K for the year ended June 2, 2001, may affect the actual results achieved by the 
Company. 

End